FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:124-125 July 13, 1995 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

No one who attended the hearings on isotretinoin at the Maryland headquarters of the Food and Drug Administration (FDA) in April 1988 could have failed to notice that the physicians present were split into two camps. On one side sat the dermatologists. They showed slides of patients with disfiguring acne, some of whom had threatened to commit suicide. On the other side sat the pediatricians. They showed slides of patients ravaged by prenatal exposure to isotretinoin, now profoundly handicapped physically and mentally. The first group pleaded that isotretinoin be allowed to remain on the market, and the second group that . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Yeargin, P. (2005). Post-marketing surveillance should include effects during pregnancy. BMJ 330: 308-308 [Full Text]  
• Vallance, P. (1996). Drugs and the fetus. BMJ 312: 1053-1054 [Full Text]